Medical options are driven primarily by our own research emanating from the DRIz. We are focused on optimising combinations of drugs and treatments in optimised sequences supported by our focus on developing improved levels of therapeutic visibility over time. We are not in the drug or device development businesses, so we are free to collaborate and partner with pharmaceutical companies and device manufacturers that can help to support and provide us with the best of breed pathways to improved efficacy.